Invention Grant
- Patent Title: Anti-IL-23 heterodimer specific antibodies
- Patent Title (中): 抗IL-23异二聚体特异性抗体
-
Application No.: US13810474Application Date: 2011-07-20
-
Publication No.: US09127057B2Publication Date: 2015-09-08
- Inventor: Adam William Clarke , Anthony G. Doyle , Matthew Pollard , Stephen Tran
- Applicant: Adam William Clarke , Anthony G. Doyle , Matthew Pollard , Stephen Tran
- Applicant Address: AU Macquarie Park, NSW
- Assignee: Teva Pharmaceuticals Ausralia Pty Ltd
- Current Assignee: Teva Pharmaceuticals Ausralia Pty Ltd
- Current Assignee Address: AU Macquarie Park, NSW
- Agency: Stradley Ronon Stevens & Young, LLP
- Priority: AU2010903234 20100720
- International Application: PCT/AU2011/000923 WO 20110720
- International Announcement: WO2012/009760 WO 20120126
- Main IPC: A61K39/395
- IPC: A61K39/395 ; C07K16/24 ; A61K39/00

Abstract:
The present disclosure provides an isolated or recombinant IL-23-binding protein comprising an antigen binding domain of an antibody, wherein the antigen binding domain specifically binds to IL-23 but does not significantly bind to an IL-12p40 subunit and does not significantly bind to an IL-23p19 subunit when they are not components of IL-23. The present disclosure also provides uses of the IL-23-binding protein.
Public/Granted literature
- US20130115166A1 ANTI-IL-23 HETERODIMER SPECIFIC ANTIBODIES Public/Granted day:2013-05-09
Information query